AR076556A1 - STABLE FORMS OF N- (2,6-DIMETIL-4-MORFOLIN-4-IL-FENIL) -3,3 -DIMETIL-BUTIRAMIDA - Google Patents

STABLE FORMS OF N- (2,6-DIMETIL-4-MORFOLIN-4-IL-FENIL) -3,3 -DIMETIL-BUTIRAMIDA

Info

Publication number
AR076556A1
AR076556A1 ARP100101588A ARP100101588A AR076556A1 AR 076556 A1 AR076556 A1 AR 076556A1 AR P100101588 A ARP100101588 A AR P100101588A AR P100101588 A ARP100101588 A AR P100101588A AR 076556 A1 AR076556 A1 AR 076556A1
Authority
AR
Argentina
Prior art keywords
dimetil
butiramida
morfolin
fenil
stable forms
Prior art date
Application number
ARP100101588A
Other languages
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42237259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076556(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR076556A1 publication Critical patent/AR076556A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Se proporcionan formas polimorficas de N-(2,6-dimetil-4-morfolin-4-il-fenil)-3,3-dimetil-butiramida, junto con un proceso para la elaboracion de dicho compuesto. Forma cristalina con XRPX en 10,36; 12,67; 28,64 y 29,98 (s2theta); forma cristalina con XRPX en 8,68; 18,09; 22,60 y 30,62 (s2theta); forma cristalina con XRPX en 8,63; 22,26; 23,40 y 30,49 (s2theta); composiciones farmacéuticas y uso para trastornos convulsivos, depresion, bipolar y esquizofrenia.Polymorphic forms of N- (2,6-dimethyl-4-morpholin-4-yl-phenyl) -3,3-dimethyl-butyramide are provided, together with a process for the preparation of said compound. Crystal form with XRPX in 10.36; 12.67; 28.64 and 29.98 (s2theta); crystalline form with XRPX in 8.68; 18.09; 22.60 and 30.62 (s2theta); crystalline form with XRPX in 8.63; 22.26; 23.40 and 30.49 (s2theta); pharmaceutical compositions and use for seizure disorders, depression, bipolar and schizophrenia.

ARP100101588A 2009-05-11 2010-05-10 STABLE FORMS OF N- (2,6-DIMETIL-4-MORFOLIN-4-IL-FENIL) -3,3 -DIMETIL-BUTIRAMIDA AR076556A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200900597 2009-05-11

Publications (1)

Publication Number Publication Date
AR076556A1 true AR076556A1 (en) 2011-06-22

Family

ID=42237259

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101588A AR076556A1 (en) 2009-05-11 2010-05-10 STABLE FORMS OF N- (2,6-DIMETIL-4-MORFOLIN-4-IL-FENIL) -3,3 -DIMETIL-BUTIRAMIDA

Country Status (23)

Country Link
EP (1) EP2430008A2 (en)
JP (1) JP2012526152A (en)
KR (1) KR20120022934A (en)
CN (1) CN102459208A (en)
AR (1) AR076556A1 (en)
AU (1) AU2010246724B2 (en)
BR (1) BRPI1013930A2 (en)
CA (1) CA2761383A1 (en)
CL (1) CL2011002814A1 (en)
CO (1) CO6460741A2 (en)
CR (1) CR20110590A (en)
DO (1) DOP2011000351A (en)
EA (1) EA201171381A1 (en)
GE (1) GEP20146006B (en)
IL (1) IL216148A0 (en)
MA (1) MA33351B1 (en)
MX (1) MX2011011885A (en)
NZ (1) NZ596738A (en)
SG (1) SG175968A1 (en)
TN (1) TN2011000557A1 (en)
TW (1) TW201041857A (en)
WO (1) WO2010130260A2 (en)
ZA (1) ZA201108112B (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
JP5419691B2 (en) * 2006-08-23 2014-02-19 バレアント ファーマシューティカルズ インターナショナル Derivatives of 4- (N-azacycloalkyl) anilide as potassium channel modulators
JP2011513196A (en) * 2007-08-01 2011-04-28 ハー・ルンドベック・アクチエゼルスカベット Use of a KCNQ potassium channel opener to alleviate symptoms of or treat a disorder or condition in which the dopaminergic system is disrupted

Also Published As

Publication number Publication date
ZA201108112B (en) 2013-01-30
TW201041857A (en) 2010-12-01
BRPI1013930A2 (en) 2019-09-24
MX2011011885A (en) 2011-12-06
CL2011002814A1 (en) 2012-04-13
TN2011000557A1 (en) 2013-05-24
DOP2011000351A (en) 2012-01-31
MA33351B1 (en) 2012-06-01
JP2012526152A (en) 2012-10-25
SG175968A1 (en) 2011-12-29
WO2010130260A3 (en) 2011-06-16
EP2430008A2 (en) 2012-03-21
WO2010130260A9 (en) 2012-10-18
CA2761383A1 (en) 2010-11-18
IL216148A0 (en) 2012-01-31
CR20110590A (en) 2012-02-22
EA201171381A1 (en) 2012-05-30
WO2010130260A2 (en) 2010-11-18
CO6460741A2 (en) 2012-06-15
AU2010246724A1 (en) 2011-12-08
AU2010246724B2 (en) 2013-03-21
CN102459208A (en) 2012-05-16
NZ596738A (en) 2013-04-26
GEP20146006B (en) 2014-01-10
KR20120022934A (en) 2012-03-12

Similar Documents

Publication Publication Date Title
ECSP078055A (en) CRYSTALLINE TIGECICLINE SOLID FORMS AND METHODS TO PREPARE THE SAME
AR061311A1 (en) PROCESSES TO PREPARE CINACALCET CHLORHYDRATE AND POLYMORPHIC FORMS OF THE SAME
MX2010004576A (en) Novel pyrimidine derivatives.
UY31344A1 (en) METANSULPHONAMIDS N- (3-TER-BUTIL-5- (2,4-DIOXO-3,4-DIHIDROPIRIMIDIN-1 (2H) -IL) -2-METOXI-ARIL) SUBSTITUTED, SOLVATOS, HYDRATS, CRYSTALLINE FORMS AND THEIR SALTS PHARMACEUTICALLY ACCEPTABLE, PREPARATION PROCESS, COMPOSITIONS AND APPLICATIONS.
HN2010001059A (en) NEW MODIFIED TITLE: COMPOUNDS DERIVED FROM PYRIMIDINE, A PROCESS FOR THE PREPARATION OF THE SAME, A PHARMACEUTICAL COMPOSITION THAT INCLUDE THEM AND COMBINATIONS OF SUCH COMPOUNDS WITH OTHER AGENTS.
BRPI0816553A2 (en) "compound, pharmaceutical composition, use of a composition, use of a compound, and process for the preparation of a compound"
ECSP109856A (en) DERIVATIVES OF OXADIAZOL AND ITS USE AS POTENTIALS OF METABOTROPIC RECEIVERS OF GLUTAMATE - 842
CR10157A (en) CHEMICAL COMPOUNDS
CR20110042A (en) CRYSTAL FORM OF (2S) - (-) - N- (6-CHLORINE-2,3-DIHYDRO-BENZO [1,4] DIOXIN-2-ILMETIL) -SULFAMIDA
CL2012002540A1 (en) Agomelatine Hydrochloride Hydrate; crystalline form; Preparation method; pharmaceutical composition; and its use for the treatment of sleep disorders, stress, anxiety, major depression, cardiovascular diseases, among others.
UY34008A (en) ? FORMS IN SOLID STATE OF HIV INHIBITOR, PHARMACEUTICAL COMPOSITION, USE OF THE SAME, AND PROCESSES TO PREPARE SUCH FORMS ?.
ECSP10010347A (en) (R) -2- (4-CYCLOPROPANSULPHONYL-PHENYL) -N-PIRAZIN-2-IL-3- (TETRAHYDROPIRAN-4-IL) -PROPIONAMIDE CRYSTALLINE
CO6551754A2 (en) 7- [3.5-DIHIDROXI-2- (3-HIDRIXI-5-PHENYL-PENT-1-ENIL) - CYCLOPENTIL] -N-ETIL-HEPT-5-ENAMIDA (BIMATOPROST) IN CRYSTAL FORM II, METHODS FOR PREPARATION AND METHOD FOR USE
UY29434A1 (en) DERIVATIVES OF TETRAHYDRONAFTALINE, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS INFLAMMATION INHIBITORS
ECSP088740A (en) TETRAHYDRONAFTALINE DERIVATIVES, PROCEDURES TO PREPARE THEM AND THEIR USE AS ANTI-INFLAMMATORIES
BR112012017188A8 (en) mglu2 agonist compound, its pharmaceutical composition and its use
PA8644701A1 (en) DERIVATIVES OF ALQUILIDEN-TETRAHIDRONAFTALENO, PROCEDURE FOR ITS PREPARATION AND ITS USE AS ANTI-INFLAMMATORIES
BRPI0515193A (en) new azabicyclohexane polymorphs
BRPI0610156A2 (en) micronized form of a compound, purified form of the compound, kit, reference standard, and method of preparing a pharmaceutical composition.
UY29481A1 (en) TETRAHYDRONAFTALINE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS ANTI-INFLAMMATORY.
DK1951738T3 (en) NEW CRYSTALLINE FORMS OF ROSTAFUROXIN
BRPI0605901A (en) polymorphic forms of tegaserode maleate
AR080203A1 (en) SOLID FORMS THAT INCLUDE A CYCLOPROPILAMIDE
CO6390054A2 (en) CRYSTAL FORMS OF A 3-CARBOXIPROPIL-AMINOTETRALINE COMPOUND
AR076556A1 (en) STABLE FORMS OF N- (2,6-DIMETIL-4-MORFOLIN-4-IL-FENIL) -3,3 -DIMETIL-BUTIRAMIDA

Legal Events

Date Code Title Description
FB Suspension of granting procedure